Opus Genetics, Inc. Authorized Dilution
Share-issuance capacity and approved equity plans, with the disclosed share class, period, approval and expiry. Gross charter headroom is authorized minus issued shares, not a forecast. Equity plan reserves may use weighted counting rules, overlap charter capacity, and must not be added to it. Outstanding awards, future grants, and proposed approvals are distinct. * denotes calculated capacity.
| As of | Authorization / plan | Share class | Authorized / approved limit (shares) | Issued shares / outstanding awards (shares) | Remaining capacity (shares / reserve units) | Approval status | Approval date | Expiry / conditions | Basis / limitations | Source |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |